Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)

• Featured article strengthens growing body of clinical evidence for Nociscan by highlighting a successful case study
  
• Special Pain issue features breakthrough innovations shaping the future of spine care
• IJSS publishes over 150 articles annually representing 40+ nations
  

BROOMFIELD, Colo., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc ., ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the publication of a featured article Tech Update, sponsored by Aclarion, in the upcoming Special Pain Issue of the International Journal of Spine Surgery (IJSS).

"The Special Pain Issue of IJSS highlights a simple truth: pain is not just a symptom-it is a complex neurobiological, psychological, and existential condition," said Morgan P. Lorio, MD, FACS, Guest Editor. "As more granular diagnostics and increasingly granular ICD-10 classifications emerge-including pre-MRS tools capable of identifying the pain generator-clinicians are gaining new ways to 'see' pain that were previously inaccessible. This edition brings together innovations that integrate objective biomarkers with clinical judgment and ultimately improve how we diagnose, treat, and prevent suffering. IJSS is publishing this issue now because the field is at an inflection point, and our patients deserve nothing less than a more complete, science-driven understanding of pain."

Aclarion's Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine for the estimated 266 million people who suffer from chronic low back pain worldwide.

In the case example highlighted, a 27-year-old patient with chronic low back pain initially underwent an MRI of the lumbar spine which visually suggested the L4/5 and L5/S1 disc levels were likely the source of this patient's pain. The treating surgeon subsequently ordered a four-level Nociscan exam to gather more information. Nociscan revealed pain biomarkers for the L5/S1 disc but not for the L4/5 disc. The surgeon utilized this information in conjunction with the MRI data and the patient's overall clinical history to limit the surgical intervention to an artificial disc replacement at only the L5/S1 disc resulting in the elimination of the patient's pain and full return to an active lifestyle.

"We are pleased that the Nociscan Tech Update is featured in the Special Pain Issue of such a high caliber journal like IJSS," said Ryan Bond, Chief Strategy Officer at Aclarion. "The journal has long been a leader among its peers for advancing scientific and clinical excellence in spine care. The Special Pain Issue is emblematic of its commitment to enhancing the science and practice of non-operative and surgical interventions to restore and improve function to the spine. Likewise, at Aclarion, we are dedicated to giving physicians new insights extracted from MR Spectroscopy (MRS) to better understand a patient's pain and differentiate between pathological pain and physiological aging."

IJSS is a prominent peer-reviewed journal and the Special Pain Issue highlights innovations that are shaping the future of spine care. The IJSS is dedicated to educating spine surgeons worldwide by reporting on the scientific basis, indications, surgical techniques, complications, outcomes, and follow-up data for promising spinal procedures. Additionally, the IJSS periodically publishes supplements, referred to as Special Issues, like the Pain Issue, to provide focused insights on high-impact areas of clinical need and innovation.

To read the advance online publication, follow this link .

To find a Nociscan center, view our site map here.

For more information on Nociscan, please email: [email protected]

All organizations cited and/or quotes from individuals not part of Aclarion have reviewed and approved the contents herein.

About Aclarion, Inc.

Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com .

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes," "will" and "expects" or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company's current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding the potential benefits of our Nociscan technology, and the Company's plans for future regulatory and commercialization activities. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contacts:

Kirin M. Smith
PCG Advisory, Inc.
[email protected]

Media Contacts:

Jessica Starman
[email protected]